Immunological and clinical changes in allergic asthmatics following treatment with omalizumab.
about
Mepolizumab versus placebo for asthmaManagement of the patient with eosinophilic asthma: a new era beginsOmalizumab: a novel therapy for allergic asthma.Omalizumab in the treatment of asthma.Airway remodelling in asthma: from benchside to clinical practice.Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.Update on optimal use of omalizumab in management of asthma.The skin prick test - European standards.Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.The impact of comorbid atopic disease on asthma: clinical expression and treatment.Anti-immunoglobulin e therapyImmunoglobulin E blockade in the treatment of asthma.Anti-IgE in allergic asthma and rhinitis: an update.Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy.Omalizumab in the treatment of severe asthma: efficacy and current problems.Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.Omalizumab treatment in brittle asthma.Diagnosis and management of eosinophilic asthma: a US perspective.Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1.Safety of omalizumab in asthma.Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.Immunological mechanisms for desensitization and tolerance in food allergy.Which biomarkers are effective for identifying Th2-driven inflammation in asthma?Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.Inhibitory effects of anti-immunoglobulin E antibodies on airway remodeling in a murine model of chronic asthma.Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.Current and future applications of the anti-IgE antibody omalizumab.Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer.Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells.Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma.Anti-IL5 therapies for asthma.Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials.Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study.Corilagin Attenuates Allergy and Anaphylactic Reaction by Inhibiting Degranulation of Mast Cells.Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma.A Woman with Asthma and Ground-Glass Opacities.
P2860
Q24186306-5BF7B87A-C56D-4FF8-91BF-F01E24065A73Q28078191-56F25D2B-AE4C-4225-8226-542A67D5DC1DQ30433722-0E15BE17-9D93-4250-985F-030AEA3FC266Q34029374-FFB73D1E-5992-4A70-B81C-DD248D6D5640Q34105688-0124B999-582B-484A-A81A-5858D188631AQ34412092-D3321B4E-78A8-441B-A960-4E363E9496DDQ34623856-07C12743-4AA7-46BC-BD78-36EE1FDB3761Q35040868-B1E3A23B-D790-4829-ACE4-290FDE6FA6E9Q35117827-5491553B-0EC8-4CA9-85E9-56E3915DFEADQ36591592-9377FCFB-0A4D-4D78-AC02-A59DE1743C88Q36765775-63034FB0-B898-4D2C-AFFC-85BAF059BCC6Q36799761-3955F4AA-ECBE-40D6-AE55-9CF4735C6096Q36834564-5FE599D8-0C99-481B-8AAD-E1D8C2A20DB9Q36951998-A03914E5-00B4-4500-A9D2-5B3B6FBDC124Q36981688-4BC3C90B-B601-4587-9355-C17368C3897CQ37102266-90221686-8AEC-4832-A5DD-7BD3C1CFAA7AQ37362658-2FD7EDC3-96CD-4E6E-AA68-98082F09BE30Q37401252-AB50BE1D-2550-49D5-99A1-7E5625BD816BQ37634330-2806209D-C35B-4009-B453-A744F010A4BAQ37708682-736BF626-FD22-44FB-B193-8CAC012D2B02Q37711418-F332C1A8-634B-4197-819E-01574D27B647Q37852717-D6453998-12DD-44AB-A18D-6CFA9168D080Q37957225-FF8A50C8-7CE0-4927-8481-48C6397A6126Q38028369-613BF461-C3F0-4E44-A2E4-6FD764574622Q38126882-4ED9A46F-6125-4817-88FA-28E96033D2F3Q38213200-8E6D0A86-A200-40A0-839C-37B6FEF54DBAQ38484785-E0C7E6E1-BC15-4AAD-B46B-F14AFF066DE3Q38982481-1E4EA6F0-3A1F-49DB-9258-81F59EFBC325Q40119246-1C5C256A-A1C3-42F9-97DB-7D14F436AB13Q41098587-EE36DCE8-01FA-4046-AFB0-9AED808EB35AQ42771088-A5061D57-C58A-4186-8AB6-9F86FB1835C3Q44917836-5732D6B7-0172-4AEF-9D1F-780A0592FF7EQ46845118-D088D5ED-4639-4909-AC5A-ACD1EEF86B95Q46865126-8F68E240-F171-4047-8DB0-03B0949D08F9Q47551081-68452500-0AE0-4E1F-A472-AAF5C8D33D7DQ47745562-0291DDD4-DDEC-4034-A100-12BE08682F3EQ48104072-037DEA26-59B4-4E15-8EED-608917F1960EQ50055695-D3361349-B59F-46B1-82C3-8179DA119B26Q52931077-5F3D960E-54D1-40C2-ADAC-2191B1B4C1C4Q53602650-CB736766-1EC9-4349-961E-A41289838CA4
P2860
Immunological and clinical changes in allergic asthmatics following treatment with omalizumab.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Immunological and clinical cha ...... ing treatment with omalizumab.
@en
Immunological and clinical cha ...... ing treatment with omalizumab.
@nl
type
label
Immunological and clinical cha ...... ing treatment with omalizumab.
@en
Immunological and clinical cha ...... ing treatment with omalizumab.
@nl
prefLabel
Immunological and clinical cha ...... ing treatment with omalizumab.
@en
Immunological and clinical cha ...... ing treatment with omalizumab.
@nl
P2093
P356
P1476
Immunological and clinical cha ...... ing treatment with omalizumab.
@en
P2093
Gerald Hanf
Gert Kunkel
Oliver Noga
P356
10.1159/000070434
P577
2003-05-01T00:00:00Z